BRIEF: BrainAurora’s revenue nearly doubles but loss widens in first half of 2025
BrainAurora Medical Technology Ltd. (6681.HK) announced on Thursday that its revenue surged 92.8% year-on-year to 100 million yuan ($14 million) in the first half of this year. But the maker…
BRIEF: Surging drug sales drive Hengrui Pharma’s profit growth
Pharmaceutical company Jiangsu Hengrui Pharmaceuticals Co. Ltd. (1276.HK; 600276.SH) saidon Wednesday that its revenue for the first half of 2025 reached 15.76 billion yuan ($2.19 billion), up 15.9% year-on-year. Its…
BRIEF: Modern Dental’s profit jumps over 30% in first half of 2025
Modern Dental Group Ltd. (3600.HK) said on Thursday it expects to report revenue of HK$1.78 billion ($226 million) to HK$1.85 billion for the first half year, up 4.3% to 8.7%…
BRIEF: Legend Biotech’s revenue rises 36% in second quarter
Drug maker Legend Biotech Corp. (LEGN.US) on Monday reported strong revenue growth in the second quarter of 2025 as its core cancer drug gained traction. But its net loss also…
BRIEF: Hutchmed’s revenue falls in first half of 2025
Drug maker Hutchmed (China) Ltd. (HCM.US; 0013.HK) reported its revenue fell in the first half of 2025, as a small gain for its best-selling drug failed to offset declines for…
BRIEF: Innogen launches $87 million Hong Kong IPO
Guangzhou Innogen Pharmaceutical Group Co. Ltd. (6603.HK) launched its Hong Kong IPO on Thursday, aiming to sell 36.56 million shares for HK$18.68 apiece to raise about HK$683 million ($87 million).…
BRIEF: YSB Inc.’s profit triples in first half of 2025
Pharmaceutical e-commerce platform YSB Inc. (9885.HK) announced on Thursday that it expects to record a net profit of 70 million yuan ($9.75 million) or more for the six months through…